Pramipexole Dihydrochloride ER Tablets 0.375mg Low price wholesale

Pramipexole Dihydrochloride ER Tablets 0.375mg Low price wholesale

$1.00

Pramipexole Dihydrochloride Extended-Release Tablets (Lisuo) deliver 0.375?mg per tablet in a sustained-release formulation. Manufactured by LIPIN Pharmaceuticals (Xiamen) Co., Ltd., this product is approved under NMPA H20213113. It is ideal for scientific research into dopaminergic modulation, Parkinson’s disease (PD), and restless legs syndrome (RLS).?? Strictly for laboratory research use only.?Please consult staff for other specifications and uses?

EMI starting from $0.00/month - View Plans
Compare

Description

Product Specifications

ParameterDetails
Product NamePramipexole Dihydrochloride Extended-Release Tablets (Lisuo)
Generic NamePramipexole Dihydrochloride
CAS Number104632-26-0
Molecular FormulaC??H??Cl?N?S
Molecular Weight302.24 g/mol
FormulationExtended-release oral tablet
Strength0.375?mg per tablet
Pack Size16 tablets per box
Dosage FormTablet
Drug Approval NumberH20213113 (NMPA – China)
Product Code86980923000021
ManufacturerLIPIN Pharmaceuticals (Xiamen) Co., Ltd.
Barcode6974026710233
Storage ConditionsStore below 25?°C, protected from light and moisture
Shelf Life24–36 months
Intended UseLaboratory research use only

Mechanism of Action

Pramipexole is a non-ergoline dopamine agonist with selectivity for the D2 and D3 dopamine receptors. It mimics dopaminergic activity in the basal ganglia, offering a neuroprotective effect. The extended-release form enables prolonged receptor stimulation, reducing fluctuations in pharmacodynamic effect in research models of Parkinson’s disease and restless legs syndrome.


Research Applications

  • Parkinson’s Disease Models
    Useful for studying motor function recovery and dopaminergic signaling in PD-induced animal models.

  • Restless Legs Syndrome (RLS)
    Employed in circadian and neurological studies to evaluate receptor activity and neuromuscular control.

  • Neuroprotection & Mitochondrial Studies
    Assessed for its antioxidative potential and mitochondrial integrity in CNS cells.

  • Extended-release Drug Delivery Studies
    Enables testing of pharmacokinetic profiles in controlled-release oral formulations.


Core Keywords

pramipexole dihydrochloride, ER tablets, extended-release pramipexole, Parkinson’s disease research, CAS 104632-26-0, restless legs syndrome lab model, dopamine receptor agonist, wholesale pramipexole, CNS drug testing, LIPIN Pharmaceuticals


Research-Use Disclaimer

This product is intended exclusively for scientific laboratory research. It is not to be used for human or animal consumption, therapeutic applications, or diagnostics. Handle using proper safety precautions and follow institutional biosafety guidelines.

Additional information

Weight1 kg
Dimensions28 × 22 × 28 cm

Reviews

There are no reviews yet.

Be the first to review “Pramipexole Dihydrochloride ER Tablets 0.375mg Low price wholesale”

Your email address will not be published. Required fields are marked *

Q1: What is the chemical identity of this product?

A1: Pramipexole Dihydrochloride with CAS Number 104632-26-0, a dopamine D2/D3 receptor agonist.

Q2: Is this product for clinical use?

A2: No. This product is strictly for research use in a laboratory setting. It is not approved for human or veterinary use.

Q3: What are typical research areas?

A3: Parkinson's disease, neurodegenerative disorders, restless legs syndrome, and CNS receptor interaction studies.

Q4: Can I get COA/SDS?

A4: Yes, Certificates of Analysis and Safety Data Sheets are available upon request.

Q5: Is bulk/wholesale available?

A5: Absolutely. We support wholesale, OEM labeling, and international export for verified research buyers.


EMI Options

Select at least 2 products
to compare